Drug Pedigree: Does It Matter to Manufacturers?


By Todd Applebaum and Uriel Kusiatin, Maxiom Group (www.maxiomgroup.com)

Manufacturers, and particularly those producing drugs meeting certain counterfeiting risk factors, cannot afford to ignore current and upcoming developments in pedigree regulations.

Click below to access this 2-page, 815KB white paper (originally published in LifeSciTech, a publication of the New Jersey Technology Council).

 | File Type: pdf

Find more white papers on Packaging

View all white papers»